Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.

Charles Herbaux,Hervé Ghesquières,Reda Bouabdallah,Stéphanie Guidez,Emmanuel Gyan,Rémi Gressin,Nadine Morineau,Loic Ysebaert,Steven Le Gouill,Camille Laurent,Hervé Tilly,Roch Houot,Gandhi Damaj,David Sibon,Pierre Feugier,Catherine Thieblemont,Corinne Haioun,Karine Tarte,Franck Morschhauser,Guillaume Cartron

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.

2021

7544Background: R/R iNHL treatment remains challenging. Atezolizumab (ATE) and obinutuzumab (OBI) are monoclonal antibodies acting respectively to inhibit T-lymphocyte exhaustion or by inducing lym...

Keywords:

Refractory
in patient
Monoclonal antibody
Obinutuzumab
Internal medicine
Oncology
Medicine
Atezolizumab
Non-Hodgkin's lymphoma
Venetoclax

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations